Skip to main navigation Skip to search Skip to main content

Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: A failed but clinically useful study

  • W. A. Nolen*
  • , R. W. Kupka
  • , G. Hellemann
  • , M. A. Frye
  • , L. L. Altshuler
  • , G. S. Leverich
  • , T. Suppes
  • , P. E. Keck
  • , S. McElroy
  • , H. Grunze
  • , J. Mintz
  • , R. M. Post
  • *Corresponding author for this work
  • University of Groningen
  • National Institutes of Health
  • Altrecht Bipolair, Utrecht, Netherlands
  • University of California at Los Angeles
  • University of Texas at Dallas
  • University of Cincinnati
  • Ludwig Maximilian University of Munich

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective: To compare the efficacy and tolerability of tranylcypromine vs. lamotrigine in bipolar depression not responding to conventional antidepressants. Method: Bipolar depressed patients received open randomized treatment with tranylcypromine or lamotrigine as add-on to a mood stabilizer during 10 weeks. In a second treatment phase, non-responding patients could receive the opposite drug. Outcome criteria were response (measured with CGI-BP and IDS-C), switch into mania, and completion of the study. Results: Only 20 of 70 planned patients were randomized, due to problems with recruitment, and 19 patients received any medication. During the first treatment phase 5/8 patients (62.5%) responded to tranylcypromine without switch into mania, compared with 4/11 patients (36.4%) on lamotrigine with two switches (statistically not significant). Over both treatment phases, 8/10 patients (80%) receiving tranylcypromine completed the study vs. 5/13 (38.5%) on lamotrigine (likelihood 0.02). Conclusion: There still appears to be a role for tranylcypromine in the treatment of refractory bipolar depression. Larger controlled studies are demanded.

Original languageEnglish
Pages (from-to)360-365
Number of pages6
JournalActa psychiatrica Scandinavica
Volume115
Issue number5
DOIs
Publication statusPublished - May 2007
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Anticonvulsant
  • Bipolar depression
  • Bipolar disorder
  • Lamotrigine
  • Lithium
  • Tranylcypromine

Fingerprint

Dive into the research topics of 'Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: A failed but clinically useful study'. Together they form a unique fingerprint.

Cite this